SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Pfizer Ltd

BSE: 500680 NSE: PFIZER ISIN: INE182A01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Pfizer Ltd belong to?
Pfizer Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Pfizer Ltd a good quality company?
Pfizer Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Pfizer Ltd undervalued or overvalued?
Pfizer Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Pfizer Ltd a good buy now?
Pfizer Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Pfizer Ltd?
Pfizer Ltd revenue growth is 4% for FY-2025 , which is above its 5 year CAGR of 1.2% , indicating faster growth.
Q.2 Gross Profit margin of Pfizer Ltd?
Pfizer Ltd Gross profit margin which is the profit after deduction of direct costs, is 37.9% for FY-2025 , which is above its 5 year median of 34.8% , indicating increasing margins.
Q.3 Operating Profit Margin of Pfizer Ltd?
Pfizer Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 32.53% for FY-2025 , which is above its 5 year median of 32.07% indicating increasing margins.
Q.4 Net Profit Margin of Pfizer Ltd?
Pfizer Ltd Net Profit Margin is 33.65% for FY-2025 , is above with its 5 year median of 25.14%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 37.9 34.8
Operating Profit Margin 32.53 32.07
Net Profit Margin 33.65 25.14
Q.5 Return on Asset of Pfizer Ltd?
Pfizer Ltd Return on Asset is 17.03%, which is above its 5 year historical median of 16.09%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd Return on equity is 19.65% for FY-2025 , which is in line with its historical median of 19.65%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Pfizer Ltd?
Pfizer Ltd Return on capital employed is 26.21% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Pfizer Ltd?
Pfizer Ltd Cash conversion cycle is 57 days, above its historical median of 23 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.53 0.58
ROE 19.65 19.65
ROCE 26.21 26.21
Cash Conversion Cycle 57 days 23 days
Q.9 Debt to Equity ratio of Pfizer Ltd?
Pfizer Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Pfizer Ltd?
Pfizer Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Pfizer Ltd?
Promoters hold 63.92% of the Pfizer Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Pfizer Ltd vs industry peers?
Pfizer Ltd revenue CAGR is 1.18% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 2,281.4 137.1
Gross Profit 864.5 15.1
Operating Profit 740 16
Net Profit 768 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.53 0.8
ROE 19.65 8.91
ROCE 26.21 11.59
Cash Conversion Cycle (days) 57.32 76

Valuation & price assessment

Q.1 Stock return of Pfizer Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 11% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 11% -1.1% 9.9% 18.6%
Q.3 Valuation ratios of Pfizer Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 26.1 42.18 40.28
Price to Book 5.58 6.24 2.77
Price to Sales 8.97 10.35 2.65
EV to EBITDA 18 26.06 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×